PropThink

About the Author PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer regular market coverage and actionable research to PropThink Premium and Premium Plus subscribers.

Portola Pharmaceuticals Inc (PTLA) Shares Bleed with Latest Drug Study Results

Drug developer and one-time Wall Street pet Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Thursday released top-line results from a phase 3 study of the oral …

Expectations for Uniqure NV’s Next Data Event: Sanfilippo Gene Therapy Results

Uniqure NV (NASDAQ:QURE)’s presentation of 1-year follow-up data from patients with Sanfilippo B (MPS IIIB) and treated with the gene therapy AMT-110 is …

A Roundup of This Week’s Market and Biotech Events: SPDR S&P 500 ETF Trust (SPY), ZS Pharma Inc (ZSPH), Relypsa Inc (RLYP)

The long-awaited September meeting of the FOMC takes place this coming Thursday. Market participants are unusually attuned to this particular meeting due to …

Despite Repeat Objections, AcelRx Pharmaceuticals Inc Must Run Another Clinical Trial

After repeat attempts to convince the U.S.

Amicus Therapeutics, Inc. (FOLD) Does Some Acquiring of Its Own

Amicus Therapeutics, Inc. (NASDAQ:FOLD), long implicated as an acquisition target by its investors, will do some acquiring of its own.

Sleep Easy Healthcare Investors; Receptos Inc (RCPT) Has Been Bought

Healthcare investors can sleep easy tonight with one of 2015’s major unanswered questions now off the table. Celgene Corporation (NASDAQ:CELG) will buy Receptos …

Celgene Corporation (CELG) Recommits To Cancer Collaboration With Epizyme (EPZM)

Just in front of its option deadline, Celgene Corporation (NASDAQ:CELG) has re-upped on an existing research and discovery collaboration with Epizyme Inc (NASDAQ:EPZM), a developer …

Celgene Corporation (CELG) Puts Up Cold Hard Cash for Access to Juno Therapeutics Inc (JUNO)’s Immunotherapies

Celgene Corporation (NASDAQ:CELG) has placed its bet in the race to develop and market T cell therapies for oncology with a $1 billion …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts